ResMed earnings per share rose in the first quarter of fiscal year 2027
ResMed reported GAAP earnings per share (EPS) of $2.92 for the first quarter of fiscal year 2027, up 23% from the prior year. Adjusted EPS was $2.91, up 14%.
Key points
- The company generated $422 million in operating cash flow for the first quarter, with free cash flow of $374 million.
- ResMed updated its presentation of restructuring and intangible asset amortization expenses this period.
Financial results and corporate events
The company generated $422 million in operating cash flow for the first quarter, with free cash flow of $374 million. It returned over $1 billion to shareholders through share repurchases and dividends.
The board of directors declared a quarterly dividend of $0.66 per share, payable on December 17, 2026. The company also completed the divestiture of MatrixCare, launched the AirTouch F40 CPAP mask, and appointed Carol Burt as lead director, effective November 15, 2026.
Michael J. Ryder, global general counsel, sold 400 shares on October 23, 2026, at a weighted average price of $255 per share under a 10b5-1 plan, a preset selling schedule executives set up in advance.
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Changes in financial reporting
ResMed updated its presentation of restructuring and intangible asset amortization expenses this period. Restructuring expenses are now classified as business transformation expenses allocated by function, rather than as a separate line item. These adjustments did not impact previously reported revenue or cash flow figures.
What to expect next
Shareholders should note the dividend payment date of December 17, 2026, and the start of Carol Burt's term as lead director on November 15, 2026.
Original sources
- 8-K filing, October 29, 2026
- 8-K EX-99.1 filing, October 29, 2026
- 144 filing, October 23, 2026
- 4 filing, October 26, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Resmed
A notification in your browser or on your phone when we publish about Resmed. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
